Sonia Poli

Light Prescriptions Innovators (Spain) — Spain

Neuroscience · Life Sciences

28h-index2.6kcitations63works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(25), Receptor Mechanisms and Signaling(16), Neuropeptides and Animal Physiology(7), Pharmacogenetics and Drug Metabolism(5), Electrochemical sensors and biosensors(4)

Publications63 total

Clinical pharmacokinetics of leriglitazone and a translational approach using <scp>PBPK</scp> modeling to guide the selection of the starting dose in children
CPT Pharmacometrics & Systems Pharmacology·2024· 2 citedOpen Access
Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease
Cells·2023· 9 citedOpen Access
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα
The Journal of Immunology·2023· 9 cited
Rescue of striatal long-term depression by chronic MGLU5 receptor negative allosteric modulation in distinct dystonia models
Journal of the Neurological Sciences·2021
Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models
Zenodo (CERN European Organization for Nuclear Research)·2021Open Access
Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models
Neuropharmacology·2021· 13 cited
MIN-102 (leriglitazone), a Brain Penetrant PPAR gamma Agonist, Decreases Neuroinflammation and Neurodegeneration and Promotes Re-Myelination in Preclinical Models of X-linked Adrenoleukodystrophy (X-ALD) (759)
Neurology·2020· 1 cited
MIN102 (Leriglitazone), a Brain Penetrant PPAR Gamma Agonist for the Treatment of Friedreich’s Ataxia (4147)
Neurology·2020· 3 cited
O5‐06‐03: SMALL MOLECULES TARGETING TAU AGGREGATION DECREASE TAU PATHOLOGY AND NEUROINFLAMMATION IN VIVO
Alzheimer s & Dementia·2019
SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours
Otology & Neurotology·2019· 6 cited
Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel H<sub>4</sub> receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects
British Journal of Clinical Pharmacology·2018· 16 citedOpen Access
ADX71943 and ADX71441, novel positive allosteric modulators of the GABA B receptor with distinct central/peripheral profiles, show efficacy in the monosodium iodoacetate model of chronic osteoarthritis pain in the rat
European Journal of Pharmacology·2016· 12 cited
The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity
Neuropharmacology·2016· 28 cited
Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
Molecular Brain·2015· 28 citedOpen Access
Potential anxiolytic- and antidepressant-like activity of Dipraglurant (ADX48621), the novel negative allosteric modulator (NAM) of the metabotropic glutamate 5 (mGlu5) receptor
Pharmacological Reports·2015
Small Molecule Therapeutics for Schizophrenia
Topics in medicinal chemistry·2014· 17 cited
Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1 <i>H</i> )-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor
Journal of Medicinal Chemistry·2014· 56 citedOpen Access
Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders
Journal of Pharmacology and Experimental Therapeutics·2014· 69 citedOpen Access
Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia
Neuropharmacology·2014· 36 cited
Evaluation of peripheral versus central effects of <scp>GABA<sub>B</sub></scp> receptor activation using a novel, positive allosteric modulator of the <scp>GABA<sub>B</sub></scp> receptor <scp>ADX</scp>71943, a pharmacological tool compound with a fully peripheral activity profile
British Journal of Pharmacology·2014· 19 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Robert Lütjens(11), Jean‐Philippe Rocher(10), Emmanuel Le Poul(9), Françoise Girard(9), Mikhail Kalinichev(9), Vincent Mutel(8), Guillaume Duvey(7), Brice Campo(6), Isabelle Royer-Urios(6), Hasnaà Haddouk(6), Christelle Boléa(5), Terry Finn(5), Sylvain Célanire(5), Luigi Casella(5), José M. Cid(5), José Ignacio Andrés(5), Gregor J. Macdonald(5), Hilde Lavreysen(5), Andrés A. Trabanco(5), Béatrice Bonnet(5)